type 2 Inflammation and Exacerbator Profiles in COPD Patients: Real-World Data From a Brazilian Specialized Center
Author(s)
Adalberto Sperb Rubin, MD, PhD1, RODRIGO ANTONINI RIBEIRO, MSc, ScD, MD2, Miriam Allein Zago Marcolino, PhD2, Karlyse Claudino Belli, PhD3, Marcelo Ferreira Nogueira, MD, PhD1.
1Santa Casa Porto Alegre, Porto Alegre, Brazil, 2TruEvidence, Porto Alegre, Brazil, 3TruEvidence, São Paulo, Brazil.
1Santa Casa Porto Alegre, Porto Alegre, Brazil, 2TruEvidence, Porto Alegre, Brazil, 3TruEvidence, São Paulo, Brazil.
Presentation Documents
OBJECTIVES: To evaluate the profile of moderate to severe chronic obstructive pulmonary disease (COPD) patients in southern Brazil, with a special emphasis on their exacerbation risk.
METHODS: A real-world cross-sectional study was conducted using retrospective data from a cohort of COPD patients attending a specialized pulmonary outpatient clinic at a tertiary hospital in Porto Alegre, southern Brazil. For the present analysis, moderate to severe patients (according to Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2025 criteria based on airflow obstruction severity, that is, forced expiratory volume in 1 second between 30% and 70% of expected) were included. Peripheral blood counts were analyzed to assess eosinophil levels, with a threshold of ≥300cells/μL used to indicate type 2 inflammation. Data collection included demographic characteristics, clinical history, spirometry results, and laboratory findings. Results are presented as mean, absolute and relative frequency.
RESULTS: Among the 255 patients initially evaluated, 243 had at least one documented blood eosinophils measurement and were included in the analysis. A total of 167 (68.7%) were receiving triple therapy (inhaled long-acting beta-agonist, anti-muscarinic and corticosteroids), of which 44 (26.3%) had had eosinophils above or equal 300. In this subgroup, 14 (31.8%) had at least one severe or two moderate exacerbations in the previous 12 months.
CONCLUSIONS: Despite almost 70% of the patients receiving optimized triple therapy, about one third of patients with blood eosinophil levels ≥300 cells/μL, indicating the presence of type 2 inflammation, experienced at least one severe or two moderate exacerbations in the previous 12 months. This information suggests that they could benefit from future treatments with biologic therapies.
METHODS: A real-world cross-sectional study was conducted using retrospective data from a cohort of COPD patients attending a specialized pulmonary outpatient clinic at a tertiary hospital in Porto Alegre, southern Brazil. For the present analysis, moderate to severe patients (according to Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2025 criteria based on airflow obstruction severity, that is, forced expiratory volume in 1 second between 30% and 70% of expected) were included. Peripheral blood counts were analyzed to assess eosinophil levels, with a threshold of ≥300cells/μL used to indicate type 2 inflammation. Data collection included demographic characteristics, clinical history, spirometry results, and laboratory findings. Results are presented as mean, absolute and relative frequency.
RESULTS: Among the 255 patients initially evaluated, 243 had at least one documented blood eosinophils measurement and were included in the analysis. A total of 167 (68.7%) were receiving triple therapy (inhaled long-acting beta-agonist, anti-muscarinic and corticosteroids), of which 44 (26.3%) had had eosinophils above or equal 300. In this subgroup, 14 (31.8%) had at least one severe or two moderate exacerbations in the previous 12 months.
CONCLUSIONS: Despite almost 70% of the patients receiving optimized triple therapy, about one third of patients with blood eosinophil levels ≥300 cells/μL, indicating the presence of type 2 inflammation, experienced at least one severe or two moderate exacerbations in the previous 12 months. This information suggests that they could benefit from future treatments with biologic therapies.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD129
Topic
Real World Data & Information Systems
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)